The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Abstract
Key Points: IDH1 promotes leukemogenesis in vivo in cooperation with HoxA9. Pharmacologic inhibition of mutant IDH1 efficiently inhibits AML cells of IDH1-mutated patients but not of normal CD34+ bone marrow cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in vivo transplantation experiments have shown that the overexpression of HOXA9 dysregulates MAPK signalling and collaborates with IDH1R132H to induce a short-latency AML in mice.9”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [9]
In the citing paper
“The homeobox protein HOXA9 contributes to haematopoiesis and is frequently overexpressed in human AMLs,8 notably in patients harbouring the IDH1R132H mutation.9”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [9]
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Research works printed but not linked: 1
- Irwin, ZINC: a free tool to discover chemistry for biology [published online ahead of print June 15, 2012]., J Chem Inf Model
Cited by
Sorted by citations
Items 201–212 of 212
Approaches to autoimmune diseases using epigenetic therapy
Hedrich, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18661-5.00024-5
Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1
Pratz, K. W. (2024) · British Journal of Haematology · doi:10.1111/bjh.19959
Pharmacoepigenetics of systemic lupus erythematosus
Hedrich, C. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00036-0
Lysine- R 2HGylation identified as a post-translational modification in R 2HG-elevated cancersPreprint
Zhao, Q., Huang, P., Yuan, C., Xia, P., Gu, Q., Yang, T., Li, X., Tian, R., & Yang, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.03.680013
“As the key mediator of oncogenicity induced by IDH1/2 mutants (IDH1/2 mut ), R 2HG has been shown to drive cancer progression 1,2 through multiple mechanisms, including metabolic and energetic reprogramming 1,17-23 , epigenetic and signaling desregulation 18,23-28 , and modulation of the tumor…”
A Review of Recent Developments in Schiff Base Derivatives for Cancer Treatment
Ngu, C. P., Sahu, R., Shah, K., Paliwal, D., Sah, A. K., & Thakur, A. (2025) · Current Organic Chemistry · doi:10.2174/0113852728405259250924102913
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib
Chien, K. S., Loghavi, S., Sasaki, K., McCue, D. A., Daver, N. G., Kadia, T. M., Ravandi, F., Short, N. J., Issa, G. C., Bravo, G. M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.001
Isocitrate Dehydrogenases Idh1 and Idh2 Regulate Pronephric Morphogenesis in Xenopus laevis
Lee, H.-K., Lee, H., Kim, C., & Lee, H. (2026) · Development & Reproduction · doi:10.12717/dr.2026.30.1.39
Wohlan, K., Fan, D., Guzman, A. G., Quezada, A., Park, H., Khabusheva, E., Sivandzade, F., Wither, M. J., Alcorn, A., Thevarajah, T. S., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100236
Metabolic Adaptation in Reprogrammed Cancer Cells
Marks, K. M., & Kung, C. K.-H. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9545-1_7
Metadata
- Authors
- Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., Meyer, J., Haemmerle, R., Struys, E. A., Jansen, E. E., Modlich, U., Li, Z., Sly, L. M., Geffers, R., Lindner, R., Manstein, D. J., Lehmann, U., Krauter, J., Ganser, A., & Heuser, M.
- Affiliations
- Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation,
- Institute of Experimental Hematology, and
- Medizinische Hochschule Hannover (DE)
- Vrije Universiteit Amsterdam (NL)
- University of British Columbia (CA)
- Helmholtz Centre for Infection Research (DE)
- Institute of Cell Biology (UA)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-10-17
- Volume
- 122
- Issue
- 16
- Pages
- 2877-2887
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2071370702
- Cited by
- 210
- References
- 45
- Citations by year
- 2026: 2 · 2025: 14 · 2024: 9 · 2023: 7 · 2022: 8 · 2021: 15 · 2020: 18 · 2019: 14 · 2018: 19 · 2017: 23 · 2016: 18 · 2015: 26 · 2014: 35 · 2013: 2
- FWCI
- 19.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, isocitrate dehydrogenase, acute myeloid leukemia, leukemogenesis, 2-hydroxyglutarate, HOXA9, myeloproliferative neoplasms, CDKN2A, CDKN2B, MAPK signaling, IDH1 inhibitor, therapeutic target
- MeSH terms
- Adolescent, Adult, Animals, Cell Cycle, Female, Humans, Isocitrate Dehydrogenase, Mice, Inbred C57BL, Middle Aged, Mutation, Leukemia, Myeloid, Acute, Gene Expression Regulation, Leukemic, Bone Marrow Transplantation, Apoptosis, Antigens, CD34, MAP Kinase Signaling System, Mice, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
